Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
RBC Capital Markets Initiates Coverage On This ‘Well Positioned’ Pet Company
RBC Capital Markets initiated Petco Health and Wellness Company Inc (NASDAQ: WOOF) with an Outperform rating and a $17 price target.
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Mizuho Securities assumes coverage of Axsome Therapeutics Inc (NASDAQ:AXSM), with a Buy rating and a price target of $76, representing a 25%…
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
SpringWorks Therapeutics Inc (NASDAQ:SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE:GSK) for SpringWorks’ nirogacestat with…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
Key Takeaways:
JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down. Large-scale market expansion is not going to be easy
The company is undervalued compared with its peers pending further progress in commercializing its products
By Molly Wen
After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge
Imara Inc (NASDAQ:IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.…
Pfizer Gets FDA Breakthrough Therapy Designation For GBS Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE: PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.
This Small Biotech Company Touts Promising Data For Alzheimer’s Candidate
BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…